Literature DB >> 20556221

A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of Schizophrenia.

R Andrew Chambers1.   

Abstract

Nicotine addiction is the leading cause of premature illness and death in the general population. Up to half of all cigarettes are consumed by a minority of the population: persons with schizophrenia and other forms of mental illness. Ironically, despite nicotine dependence being considered a serious and deadly form of addiction in the general population, research on smoking in mental illness is predominantly guided by the idea that smoking has beneficial medication-like treatment effects. This article considers pitfalls of adherence to the self-medication hypothesis as an exclusively held dogma. New evidence from animal modeling work suggests the need to broaden hypothesis-driven research on smoking in mental illness. Adolescent smoking could predispose to mental illness and/or increased nicotine dependence in schizophrenia may represent an involuntary, general addiction vulnerability that has little to do with the 'helpful' psychoactive effects of nicotine or other drugs.

Entities:  

Year:  2009        PMID: 20556221      PMCID: PMC2885739          DOI: 10.1080/15504260902869808

Source DB:  PubMed          Journal:  J Dual Diagn        ISSN: 1550-4271


  38 in total

1.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

2.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

Review 3.  Smoking and mental illness.

Authors:  S Leonard; L E Adler; K Benhammou; R Berger; C R Breese; C Drebing; J Gault; M J Lee; J Logel; A Olincy; R G Ross; K Stevens; B Sullivan; R Vianzon; D E Virnich; M Waldo; K Walton; R Freedman
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

Review 4.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

5.  Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.

Authors:  Ahmadul Kadir; Taher Darreh-Shori; Ove Almkvist; Anders Wall; Bengt Långström; Agneta Nordberg
Journal:  Psychopharmacology (Berl)       Date:  2007-02-20       Impact factor: 4.530

6.  Increased CRF-like and NPY-like immunoreactivity in adult rats exposed to nicotine during adolescence: relation to anxiety-like and depressive-like behavior.

Authors:  Craig J Slawecki; Annika K Thorsell; Aram El Khoury; Aleksander A Mathé; Cindy L Ehlers
Journal:  Neuropeptides       Date:  2005-08       Impact factor: 3.286

7.  Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.

Authors:  B K Lipska; G E Jaskiw; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  1993-08       Impact factor: 7.853

8.  Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Sarah A Berg; R Andrew Chambers
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

9.  Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia.

Authors:  Anne Marie Brady; Sarah E McCallum; Stanley D Glick; Patricio O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2008-05-26       Impact factor: 4.530

10.  Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.

Authors:  B K Lipska; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  1994-05       Impact factor: 7.853

View more
  7 in total

Review 1.  Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders.

Authors:  R Andrew Chambers
Journal:  Drug Alcohol Depend       Date:  2012-12-29       Impact factor: 4.492

Review 2.  The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update.

Authors:  John J Mariani; Edward J Khantzian; Frances R Levin
Journal:  Am J Addict       Date:  2013-09-13

3.  Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.

Authors:  Douglas L Boggs; Toral S Surti; Irina Esterlis; Brian Pittman; Kelly Cosgrove; R Andrew Sewell; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

Review 4.  Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems.

Authors:  Kristen M Mackowick; Mera S Barr; Victoria C Wing; Rachel A Rabin; Clairelaine Ouellet-Plamondon; Tony P George
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-07-19       Impact factor: 5.067

Review 5.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

Review 6.  Impact of tobacco regulation on animal research: new perspectives and opportunities.

Authors:  Eric C Donny; Tracy G Taylor; Mark G LeSage; Melissa Levin; Deanne M Buffalari; Danielle Joel; Alan F Sved
Journal:  Nicotine Tob Res       Date:  2012-09-04       Impact factor: 4.244

7.  An Idiographic Examination of Day-to-Day Patterns of Substance Use Craving, Negative Affect and Tobacco Use among Young Adults in Recovery.

Authors:  Yao Zheng; Richard P Wiebe; H Harrington Cleveland; Peter C M Molenaar; Kitty S Harris
Journal:  Multivariate Behav Res       Date:  2013       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.